BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
BCLI Stock | USD 1.60 0.01 0.62% |
Under 63% of Brainstorm Cell's investor base is looking to short. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that many traders are alarmed. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
Brainstorm |
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
Read at finance.yahoo.com
Brainstorm Cell Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Brainstorm Cell Fundamental Analysis
We analyze Brainstorm Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Brainstorm Cell is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Brainstorm Cell Ther Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Brainstorm Cell stock to make a market-neutral strategy. Peer analysis of Brainstorm Cell could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics with similar companies.
Peers
Brainstorm Cell Related Equities
TRVI | Trevi Therapeutics | 18.33 | ||||
XFOR | X4 Pharmaceuticals | 16.58 | ||||
TERN | Terns Pharmaceuticals | 1.67 | ||||
GRI | GRI Bio | 0.71 | ||||
BCAB | Bioatla | 0.70 | ||||
INZY | Inozyme Pharma | 0.67 | ||||
PASG | Passage Bio | 0.38 | ||||
EWTX | Edgewise Therapeutics | 0.43 | ||||
MREO | Mereo BioPharma | 0.80 | ||||
CELC | Celcuity LLC | 1.03 | ||||
ALDX | Aldeyra | 1.20 | ||||
PLX | Protalix Biotherapeutics | 1.67 | ||||
ANTX | AN2 Therapeutics | 2.03 | ||||
CCCC | C4 Therapeutics | 2.78 | ||||
DAWN | Day One | 2.89 | ||||
CKPT | Checkpoint Therapeutics | 3.16 | ||||
GBIO | Generation Bio | 4.20 | ||||
HOWL | Werewolf Therapeutics | 4.68 | ||||
HCWB | HCW Biologics | 4.87 | ||||
CUE | Cue Biopharma | 5.60 | ||||
CNTB | Connect Biopharma | 6.50 | ||||
CRVS | Corvus Pharmaceuticals | 8.29 |
Complementary Tools for Brainstorm Stock analysis
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Stocks Directory Find actively traded stocks across global markets | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |